TABLE-3.
Trastuzumab Users Only - Patient Characteristics According to Recommended Cardiac Monitoring Among Trastuzumab-Treated Breast Cancer Patients (N=4325).
| Recommended Cardiac Monitoring | |||
|---|---|---|---|
| Patient Characteristic | Total; N | Yes; N (%) | P |
| All Patients | 4325 | 1997 (46.2) | <0.001 |
| Heart Failure | <0.001 | ||
| No | 3965 | 1789 (45.1) | |
| Yes | 360 | 208 (57.8) | |
| Age, years | 0.457 | ||
| <35 | 112 | 45 (40.2) | |
| 36–49 | 1019 | 485 (47.6) | |
| 50–64 | 2381 | 1097 (46.1) | |
| 65+ | 813 | 370 (45.5) | |
| Year of Diagnosis | 0.166 | ||
| 2009 | 733 | 339 (46.2) | |
| 2010 | 816 | 350 (42.9) | |
| 2011 | 801 | 341 (42.6) | |
| 2012 | 652 | 319 (48.9) | |
| 2013 | 710 | 375 (52.8) | |
| 2014 | 512 | 273 (53.3) | |
| Anthracyclines | <0.001 | ||
| No | 3574 | 1579 (44.2) | |
| Yes | 751 | 418 (55.7) | |
| Taxanes | <0.001 | ||
| No | 327 | 114 (34.9) | |
| Yes | 3998 | 1883 (47.1) | |
| Radiation | 0.002 | ||
| No | 1631 | 703 (43.1) | |
| Yes | 2694 | 1294 (48.0) | |
| Deyo Comorbidity Score | 0.959 | ||
| 0 | 3383 | 1559 (46.1) | |
| 1 | 738 | 342 (46.3) | |
| 2+ | 204 | 96 (47.1) | |
| Hypertension | 0.471 | ||
| No | 2804 | 1306 (46.6) | |
| Yes | 1521 | 691 (45.4) | |
| Diabetes | 0.320 | ||
| No | 3849 | 1767 (45.9) | |
| Yes | 476 | 230 (48.3) | |
| Coronary Artery Disease | 0.595 | ||
| No | 4159 | 1917 (46.1) | |
| Yes | 166 | 80 (48.2) | |
| Valve Disease | 0.737 | ||
| No | 4147 | 1917 (46.2) | |
| Yes | 178 | 80 (44.9) | |
| Insurance | 0.113 | ||
| PPO | 2538 | 1141 (45.0) | |
| HMO | 484 | 224 (46.3) | |
| Other | 1303 | 632 (48.5) | |
| Region | 0.005 | ||
| North Central | 1049 | 508 (48.4) | |
| Northeast | 740 | 363 (49.1) | |
| South | 1676 | 769 (45.9) | |
| Unknown | 73 | 37 (50.7) | |
| West | 787 | 320 (40.7) | |
*
P<0.05.